Compare AstraZeneca plc (AZN) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Wix.Com Ltd — how do they compare? AstraZeneca plc trades at $158.56 (market cap $248.14B), while Wix.Com Ltd trades at $67.64 (market cap $2.79B). The key difference: AstraZeneca plc is far larger — about 88.9× Wix.Com Ltd's market cap, and AstraZeneca plc pays a 2.01% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals.
| AZN | WIX | |
|---|---|---|
Market Cap | $248.14B | $2.79B |
Sector | Health | Technology |
52-Week High | $209.48 | $184.24 |
52-Week Low | $147.06 | $40.43 |
Enterprise Value | $275.41B | $3.87B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
WIX trades at $66.60, up 6.69% today, with a bullish technical signal from moving averages and a consensus analyst price target of $79.75. Revenue grew to $1.99B in 2025, though net income margin remains negative at -8.19%. Recent news includes the launch of Symphony by Wix, an AI system for SMBs, but the stock faces multiple class-action lawsuits following a 27% drop after Q1 2026 earnings missed expectations.
The outlook is mixed: strong revenue growth and analyst buy ratings suggest upside, but legal risks and volatile earnings pose significant challenges. Investors should weigh the high P/E of 62.84 against competitive pressures in the website-building space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
